Abstract
Rationale
Although reports of dextromethorphan (DXM) abuse have increased recently, few studies have examined the effects of high doses of DXM.
Objective
This study in humans evaluated the effects of supratherapeutic doses of DXM and triazolam.
Methods
Single, acute oral doses of DXM (100, 200, 300, 400, 500, 600, 700, and 800 mg/70 kg), triazolam (0.25 and 0.5 mg/70 kg), and placebo were administered to 12 healthy volunteers with histories of hallucinogen use, under double-blind conditions, using an ascending dose run-up design. Subjective, behavioral, and physiological effects were assessed repeatedly after drug administration for 6 h.
Results
Triazolam produced dose-related increases in subject-rated sedation, observer-rated sedation, and behavioral impairment. DXM produced a profile of dose-related physiological and subjective effects differing from triazolam. DXM effects included increases in blood pressure, heart rate, and emesis; increases in observer-rated effects typical of classic hallucinogens (e.g., distance from reality, visual effects with eyes open and closed, joy, anxiety); and participant ratings of stimulation (e.g., jittery, nervous), somatic effects (e.g., tingling, headache), perceptual changes, end-of-session drug liking, and mystical-type experience. After 400 mg/70 kg DXM, 11 of 12 participants indicated on a pharmacological class questionnaire that they thought they had received a classic hallucinogen (e.g., psilocybin). Drug effects resolved without significant adverse effects by the end of the session. In a 1-month follow-up, volunteers attributed increased spirituality and positive changes in attitudes, moods, and behavior to the session experiences.
Conclusions
High doses of DXM produced effects distinct from triazolam and had characteristics that were similar to the classic hallucinogen psilocybin.
Similar content being viewed by others
References
Addy PH (2012) Acute and post-acute behavioral and psychological effects of Salvinorin A in humans. Psychopharmacology (Berl) 220:195–204
Aghajanian GK, Marek GJ (1999) Serotonin and hallucinogens. Neuropsychopharmacology 21:16S–23S
Banken JA, Foster H (2008) Dextromethorphan. Ann N Y Acad Sci 1139:402–411
Barnhart JW (1980) The urinary excretion of dextromethorphan and three metabolites in dogs and humans. Toxicol Appl Pharmacol 55:43–48
Bem JL, Peck R (1992) Dextromethorphan. An overview of safety issues. Drug Saf 7:190–199
Bobo WV, Miller SC, Martin BD (2005) The abuse liability of dextromethorphan among adolescents: a review. J Child Adolesc Subst Abuse 14(4):55–75
Boyer EW (2004) Dextromethorphan abuse. Pediatr Emerg Care 20:858–863
Bryner JK, Wang UK, Hui JW, Bedodo M, MacDougall C, Anderson IB (2006) Dextromethorphan abuse in adolescence: an increasing trend: 1999–2004. Arch Pediatr Adolesc Med 160:1217–1222
Carter LP, Richards BD, Mintzer MZ, Griffiths RR (2006) Relative abuse liability of GHB in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology 31:2537–2551
Carter LP, Griffiths RR, Mintzer MZ (2009) Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacology (Berl) 206:141–154
Church J (1990) Dextromethorphan, dysphoria and NMDA receptors. Neuromodulatory effects of dextromethorphan: role of NMDA receptors in responses. Trends Pharmacol Sci 11:146–147
Church J, Sawyer D, McLarnon JG (1994) Interactions of dextromethorphan with the N-methyl-D-aspartate receptor-channel complex: single channel recordings. Brain Res 666:189–194
Falck R, Li L, Carlson R, Wang J (2006) The prevalence of dextromethorphan abuse among high school students. Pediatrics 118:2267–2269
Fantegrossi WE, Murnane KS, Reissig CJ (2008) The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75:17–33
Forrester MB (2011) Dextromethorphan abuse in Texas, 2000–2009. J Addict Dis 30:243–247
Franklin PH, Murray TF (1992) High affinity [3H]dextrorphan binding in rat brain is localized to a noncompetitive antagonist site of the activated N-methyl-D-aspartate receptor-cation channel. Mol Pharmacol 41:134–146
Fribourg M, Moreno JL, Holloway T et al (2011) Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147:1011–1023
Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, Hermle L, Spitzer M, Sass H (1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl) 142:41–50
Griffiths RR, Johnson MW (2005) Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 66(Suppl 9):31–41
Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187:268–28
Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl) 218:649–665
Holtzman SG (1982) Phencyclidine-like discriminative stimulus properties of opioids in the squirrel monkey. Psychopharmacology (Berl) 77:295–300
Holtzman SG (1994) Discriminative stimulus effects of dextromethorphan in the rat. Psychopharmacology (Berl) 116:249–254
Hood RW Jr, Hill PC, Spilka B (2009) The psychology of religion: an empirical approach, 4th edn. Guilford, New York
Johanson CE, Kilbey M, Gatchalian K, Tancer M (2006) Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend 81:27–36
Johnson M, Richards W, Griffiths R (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22:603–620
Lofwall MR, Griffiths RR, Mintzer MZ (2006) Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults. Exp Clin Psychopharmacol 14:439–449
Metzner R, Litwin G, Weil G (1965) The relation of expectation and mood to psilocybin reactions: a questionnaire study. Psychedelic Rev 5:3–39
Mintzer MZ, Griffiths RR (2005) An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers. Behav Pharmacol 16:579–584
Morris BJ, Cochran SM, Pratt JA (2005) PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 5:101–106
Mumford GK, Rush CR, Griffiths RR (1995) Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J Pharmacol Exp Ther 272:570–580
Murray TF, Leid ME (1984) Interaction of dextrorotatory opioids with phencyclidine recognition sites in rat brain membranes. Life Sci 34:1899–1911
Newell KA, Zavitsanou K, Huang XF (2007) Short and long term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment. J Neural Transm 114:995–1001
Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181
Nicholson KL, Hayes BA, Balster RL (1999) Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys. Psychopharmacology (Berl) 146:49–59
Pahnke WN (1969) Psychedelic drugs and mystical experience. Int Psychiatry Clin 5:149–162
Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34:1239–1258
Riba J, Rodriguez-Fornells A, Strassman RJ, Barbanoj MJ (2001) Psychometric assessment of the Hallucinogen Rating Scale. Drug Alcohol Depend 62:215–223
Richards WA, Rhead JC, DiLeo FB, Yensen R, Kurland AA (1977) The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychedelic Drugs 9:1–10
Romanelli F, Smith KM (2009) Dextromethorphan abuse: clinical effects and management. J Am Pharm Assoc 49:e20–e25
Rush CR, Frey JM, Griffiths RR (1999) Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology (Berl) 145:39–51
Schmid B, Bircher J, Preisig R, Kupfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618–624
Schutz CG, Soyka M (2000) Dextromethorphan challenge in alcohol-dependent patients and controls. Arch Gen Psychiatry 57:291–292
Sinner B, Graf BM (2008) Ketamine. Handb Exp Pharmacol 182:313–333
Soyka M, Bondy B, Eisenburg B, Schutz CG (2000) NMDA receptor challenge with dextromethorphan—subjective response, neuroendocrinological findings and possible clinical implications. J Neural Transm 107:701–714
Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose–response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98–108
Tancer ME, Johanson CE (2001) The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 65:97–101
Tancer M, Johanson CE (2003) Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend 72:33–44
Turek IS, Soskin RA, Kurland AA (1974) Methylenedioxyamphetamine (MDA) subjective effects. J Psychedelic Drugs 6:7–14
Vengurlekar SS, Heitkamp J, McCush F, Velagaleti PR, Brisson JH, Bramer SL (2002) A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine—application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition. J Pharm Biomed Anal 30:113–124
Vollenweider FX, Kometer M (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11:642–651
Werling LL, Keller A, Frank JG, Nuwayhid SJ (2007) A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol 207:248–257
Wilson MD, Ferguson RW, Mazer ME, Litovitz TL (2011) Monitoring trends in dextromethorphan abuse using the National Poison Data System: 2000–2010. Clin Toxicol (Phila) 49:409–415
Winter JC, Doat M, Rabin RA (2000) Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists: a link between the glutamatergic and serotonergic hypotheses of schizophrenia. Life Sci 68:337–344
Winter JC, Eckler JR, Rice KC, Rabin RA (2005) Serotonergic/glutamatergic interactions: potentiation of phencyclidine-induced stimulus control by citalopram. Pharmacol Biochem Behav 81:694–700
Wolfinger R, Chang M (1995) Comparing the SAS GLM and MIXED procedures for repeated measurements analysis. SUGI Proc 1995:1–11
Young AM, Herling S, Winger GD, Woods JH (1981) Comparison of discriminative and reinforcing effects of ketamine and related compounds in the rhesus monkey. NIDA Res Monogr 34:173–179
Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM (1998) Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. J Clin Psychopharmacol 18:332–337
Zawertailo LA, Tyndale RF, Busto U, Sellers EM (2010) Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Hum Psychopharmacol 25:71–79
Ziaee V, Akbari HE, Hoshmand A, Amini H, Kebriaeizadeh A, Saman K (2005) Side effects of dextromethorphan abuse, a case series. Addict Behav 30:1607–1613
Acknowledgments
This research was supported by NIDA grant DA003889. We would like to thank Mary Cosimano, M.S.W., Lilian Salinas, and Jenna Cohen for serving as assistant session monitors. We thank John Yingling for technical assistance, Barine Duman Majewska, J.D. for database programming, and Linda Felch for statistical assistance. The study was conducted in compliance with United States laws.
Disclosures
Lawrence Carter is a current employee of Jazz Pharmaceuticals and owns stock and stock options in the company.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOC 89.5 kb)
Rights and permissions
About this article
Cite this article
Reissig, C.J., Carter, L.P., Johnson, M.W. et al. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology 223, 1–15 (2012). https://doi.org/10.1007/s00213-012-2680-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-012-2680-6